Literature DB >> 35819840

Lipoprotein subfractions and subclinical vascular health in middle aged women: does menopause status matter?

Meiyuzhen Qi1, Xirun Chen1, Ronald M Krauss2, Karen Matthews, Imke Janssen3, Maria M Brooks1, Dan McConnell4, Sybil L Crawford5, Samar R El Khoudary1.   

Abstract

OBJECTIVE: During midlife, women experience changes in lipoprotein profiles and deterioration in vascular health measures. We analyzed the associations of groups of lipoprotein subfractions as determined by principal component analysis (PCA) with subclinical vascular health measures in midlife women and tested if these associations were modified by menopause status.
METHODS: PCA was used to generate principal components (PCs) from 12 lipoprotein subfractions quantified among 545 midlife women. The associations of the identified PCs and concurrent vascular health measures were assessed using linear or logistic regressions among participants with carotid intima-media thickness (cIMT; n = 259), coronary artery calcium (n = 249), or aortic calcium (n = 248) scores.
RESULTS: PCA generated four PCs representing groups of (1) small, medium, and large very low-density lipoproteins subclasses-very low-density lipoprotein PC; (2) very small, small, and medium low-density lipoprotein (LDL) subclasses-small-medium LDL-PC; (3) large and small high-density lipoproteins subclasses and midzone particles-high-density lipoprotein PC; and (4) large LDL and small intermediate-density lipoproteins-large LDL-PC. Small-medium LDL-PC was positively associated with cIMT, coronary artery calcium, and aortic calcium in unadjusted but not in adjusted models. Menopause status modified the positive association of the small-medium LDL-PC with cIMT (interaction P = 0.02) such that this association was stronger after versus before menopause ( P = 0.01).
CONCLUSIONS: Carotid intimal medial thickening is positively and independently associated with small- and medium-sized LDL particles after menopause. Monitoring levels of specific lipoprotein fractions may have value in identifying midlife women at risk for developing atherosclerotic vascular disease.
Copyright © 2022 by The North American Menopause Society.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35819840      PMCID: PMC9339472          DOI: 10.1097/GME.0000000000001998

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   3.310


  36 in total

1.  The Scree Test For The Number Of Factors.

Authors:  R B Cattell
Journal:  Multivariate Behav Res       Date:  1966-04-01       Impact factor: 5.923

2.  Effects of estrogen on susceptibility to oxidation of low-density and high-density lipoprotein in postmenopausal women.

Authors:  A Wakatsuki; N Ikenoue; Y Sagara
Journal:  Maturitas       Date:  1998-01-12       Impact factor: 4.342

3.  All low-density lipoprotein particles are not created equal.

Authors:  Ronald M Krauss
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-05       Impact factor: 8.311

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Progression rates of carotid intima-media thickness and adventitial diameter during the menopausal transition.

Authors:  Samar R El Khoudary; Rachel P Wildman; Karen Matthews; Rebecca C Thurston; Joyce T Bromberger; Kim Sutton-Tyrrell
Journal:  Menopause       Date:  2013-01       Impact factor: 2.953

6.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

7.  Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.

Authors:  Samia Mora; Michael P Caulfield; Jay Wohlgemuth; Zhihong Chen; H Robert Superko; Charles M Rowland; Robert J Glynn; Paul M Ridker; Ronald M Krauss
Journal:  Circulation       Date:  2015-09-25       Impact factor: 29.690

8.  HDL (High-Density Lipoprotein) Subclasses, Lipid Content, and Function Trajectories Across the Menopause Transition: SWAN-HDL Study.

Authors:  Samar R El Khoudary ( سمر رياض الخضري ); Xirun Chen (陈曦润); Alexis Nasr ( ألكسس نصر ); Jeff Billheimer; Maria Mori Brooks; Dan McConnell; Trevor J Orchard; Sybil L Crawford; Karen A Matthews; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-03       Impact factor: 8.311

9.  Progression of Metabolic Syndrome Severity During the Menopausal Transition.

Authors:  Matthew J Gurka; Abhishek Vishnu; Richard J Santen; Mark D DeBoer
Journal:  J Am Heart Assoc       Date:  2016-08-03       Impact factor: 5.501

Review 10.  Cardiovascular risk and obesity.

Authors:  C Cercato; F A Fonseca
Journal:  Diabetol Metab Syndr       Date:  2019-08-28       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.